Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
CAMBRIDGE, Mass. and EXTON, Pa., Aug. 11, 2017 -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that the company will provide a corporate overview and participate in a fireside chat, led by Joanna Horobin, M.B. Ch.B., Idera’s Chief Medical Officer at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at 9:45 a.m. Eastern Time at the Le Parker Meridien Hotel in New York City.
Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. Archived versions will also be available on the Company’s website after the event for 90 days.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) [email protected]
